ArticleQatar medical journal2026
Bridging morphology and genomics: p53, mismatch repair proteins, and β-catenin as immunohistochemistry surrogates for risk stratification in endometrial carcinoma.
Article in Qatar medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Molecular Pathology of Morules in Endometrial Carcinoma: Biological Significance and Clinical Implications.Pathology international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometrial carcinoma (EC) is the most frequent gynecologic cancer in developed countries, with considerable biological heterogeneity. The Cancer Genome Atlas molecular classification provides important prognostic information, but genomic profiling is not always practical. Immunohistochemistry (IHC)-based surrogates using p53, mismatch repair (MMR) proteins, and β-catenin offer a practical alternative. Objective: This study aims to evaluate the prognostic value of an expanded IHC-based molecular panel (p53, MMR, β-catenin) for risk stratification, with a focus on identifying high-risk patients within the heterogeneous "no specific molecular profile" (NSMP) subgroup. Methods: This retrospective cohort study included 150 EC patients treated between 2018 and 2022. IHC classified cases as p53-abnormal (p53abn), MMR-deficient (MMRd), or p53-wild type (NSMP). Nuclear β-catenin (surrogate for CTNNB1 mutation) was assessed. Survival analysis used Kaplan-Meier and Cox regression. Results: Nuclear β-catenin positivity was found in 22.0% (33/150) of all cases and in 24.8% (26/105) of NSMP tumors. It was associated with lymphovascular space invasion (LVSI; 69.7% vs. 24.0%; Conclusion: An IHC panel incorporating p53, MMR, and β-catenin effectively stratifies EC risk. Nuclear β-catenin identifies a higher-risk subset within the prognostically heterogeneous NSMP group, supporting its integration into routine prognostic protocols to guide adjuvant therapy and surveillance, particularly in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.